We rank companies based on fund manager, research analyst and news sentiment
AKYA stock icon

Akoya BioSciences
AKYA

$3.91
1.76%
 

About: Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery, clinical research and diagnostics. Its PhenoCycler (formerly CODEX) and PhenoImager (formerly Phenoptics) platforms, reagents, software, and services, It offer end-to-end solutions to perform tissue analysis and spatial phenotyping across the full continuum from discovery through translational and clinical research and diagnostics.

Employees: 330

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 6 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

7,120% more call options, than puts

Call options by funds: $176K | Put options by funds: $2.44K

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

19% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 21

5% more funds holding

Funds holding: 62 [Q3] → 65 (+3) [Q4]

3% less capital invested

Capital invested by funds: $74.7M [Q3] → $72.1M (-$2.57M) [Q4]

2.76% less ownership

Funds ownership: 32.83% [Q3] → 30.07% (-2.76%) [Q4]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$7.5
92%
upside
Avg. target
$8.75
124%
upside
High target
$10
156%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
JP Morgan
Tycho Peterson
156%upside
$10
Overweight
Maintained
6 Mar 2024
UBS
John Sourbeer
92%upside
$7.5
Buy
Maintained
5 Mar 2024
Canaccord Genuity
Kyle Mikson
156%upside
$10
Buy
Reiterated
5 Mar 2024
Piper Sandler
David Westenberg
105%upside
$8
Overweight
Maintained
13 Nov 2023
Stephens & Co.
Mason Carrico
130%upside
$9
Overweight
Maintained
13 Nov 2023

Financial journalist opinion